drugset / Trial / NCT05805618
Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects
RandomizedParallel-groupQuadruple-blindHealth-services research
Summary
To evaluate the safety and immunogenicity of different dose levels of the Recombinant Norovirus Hexavalent Vaccine in healthy subjects aged 18-59 years given three doses of the vaccine at 28-day intervals.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2024-11-01
- Completion
- 2024-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Norovirus Hexavalent Vaccine | Unknown | 150 mg | Intramuscular |
| Subject | Recombinant Norovirus Hexavalent Vaccine | Unknown | 300 mg | Intramuscular |